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Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with
and without cribriform architecture at the time of radical prostatectomy
Abstract: Aims: Invasive cribriform and intraductal
carcinoma are associated with aggressive disease in
Grade Group 2 (GG2) prostate cancer patients. How-
ever, the characteristics and clinical outcome of
patients with GG2 prostate cancer without cribriform
architecture (GG2) as compared with those with
Grade Group 1 (GG1) prostate cancer are unknown.
The aim of this study was to investigate the clinical
and pathological characteristics of GG1 and GG2
prostate cancer in radical prostatectomy specimens.
Methods and results: We reviewed 835 radical
prostatectomy specimens for Grade Group, pT stage,
surgical margin status, and the presence of cribriform
architecture. Biochemical recurrence-free survival
and metastasis were used as clinical outcomes. GG1
prostate cancer was seen in 207 patients, and GG2
prostate cancer was seen in 420 patients, of whom
228 (54%) showed cribriform architecture (GG2+)
and 192 (46%) did not. GG2 patients had higher
prostate-specific antigen levels (9.4 ng/ml versus
7.0 ng/ml; P < 0.001), more often had extraprostatic
extension (36% versus 11%; P < 0.001) and had
more positive surgical margins (27% versus 17%;
P = 0.01) than GG1 patients. GG2 patients had
shorter biochemical recurrence-free survival (hazard
ratio 2.7, 95% confidence interval 1.4–4.9;
P = 0.002) than GG1 patients. Lymph node and dis-
tant metastasis were observed neither in GG2 nor
in GG1 patients, but occurred in 22 of 228 (10%)
GG2+ patients.
Conclusion: In conclusion, patients with GG2 pros-
tate cancer at radical prostatectomy have more
advanced disease and shorter biochemical recurrence-
free survival than those with GG1 prostate cancer,
but both groups have a very low risk of developing
metastasis.
Keywords: cribriform, intraductal carcinoma, prognosis, prostate cancer
Introduction
Active surveillance is increasingly being applied for
patients with prostate cancer. Whereas most patients
with biopsy Grade Group 1 (Gleason score of
3 + 3 = 6, GG1) prostate cancer are eligible for active
surveillance, the inclusion of favourable Grade Group
2 (Gleason score of 3 + 4 = 7, GG2) patients with
limited Gleason pattern 4 is gradually being
accepted.1–5 In general, these patients have prostate-
specific antigen (PSA) levels of <10 ng/ml, present
with organ-confined disease, and have <10% Gleason
pattern 4 in their diagnostic biopsies.6
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Gleason pattern 4 prostate cancer is a heteroge-
neous disease encompassing various histopathological
growth patterns. Invasive and/or intraductal cribri-
form carcinoma, both also referred to as cribriform
architecture, have been identified as pathological
parameters for worse outcome in both biopsy and
radical prostatectomy specimens.7–12 Cribriform
architecture has been associated with advanced
tumour stage, biochemical recurrence, metastasis and
disease-specific death in GG2 patients.13–15 Although
patients with GG2 prostate cancer without cribriform
architecture (GG2) have favourable outcomes as
compared with those with invasive and/or intraductal
cribriform carcinoma (GG2+), it is unclear to what
extent GG2 prostate cancer differs from GG1 pros-
tate cancer.
In previous sextant biopsy studies with long-term
follow-up, biopsy GG2 patients had similar biochem-
ical recurrence-free and disease-specific survival as
GG1 patients.16,17 Therefore, it has been proposed
that patients without cribriform architecture might be
eligible for active surveillance.15–20 However, prostate
biopsies are subject to significant sampling errors
with tumour undergrading in up to 40%, and there
is low sensitivity for detection of cribriform architec-
ture.21–23 Moreover, in contrast to radical prostatec-
tomy specimens, minor high-grade patterns are
always taken into account when prostate cancer
biopsies are graded. To elucidate its clinical and bio-
logical features, GG2 prostate cancer should be
investigated on radical prostatectomy specimens,
which excludes study bias caused by biopsy sampling
artefacts. The aim of this study was to compare the
clinicopathological characteristics and biochemical
recurrence-free survival of GG1 patients and GG2
patients in radical prostatectomy specimens.
Materials and methods
P A T I E N T S E L E C T I O N
In total, 854 patients who had undergone radical
prostatectomy for prostate adenocarcinoma at Eras-
mus MC, University Medical Centre, Rotterdam, The
Netherlands between 2000 and 2017 were
included. Patients who had received hormonal, radi-
ation or viral therapy (n = 19) prior to surgery
were excluded from this study.24 After fixation in
neutral-buffered formalin, radical prostatectomy
specimens were sectioned transversely and totally
embedded for diagnostic purposes. All slides were
available for pathology review. The use of tissue
samples for scientific purposes was approved by the
institutional Medical Research Ethics Committee
(MEC-2018-1614).
P A T H O L O G I C A L E V A L U A T I O N
All 835 radical prostatectomy specimens were reviewed
by two investigators (E.H. and G.G.L.H.v.L), who were
blinded to clinical outcome. The following features were
recorded: Gleason score and Grade Group according to
the World Health Organization 2016 guidelines, pT
stage according to the American Joint Committee on
cancer TNM 8th edition, surgical margin status, Glea-
son pattern 3 to 5 percentages, Gleason 4 growth pat-
terns, and the presence of intraductal carcinoma.25–27
Tertiary Gleason patterns occupied <5% of the total
tumour area.25,27 Intraductal carcinoma and tertiary
Gleason patterns were not incorporated in the Gleason
score. Invasive cribriform Gleason grade 4 was morpho-
logically distinguished from intraductal carcinoma
when it had an irregular outline, anastomosing fields
beyond pre-existing gland architecture, or extension
into periprostatic fat tissue, ejaculatory ducts, or seminal
vesicles. Intraductal carcinoma was morphologically
identified if cribriform structures were clearly continu-
ous with pre-existing glands lined by normal basal
epithelium, or containing corpora amylacea. When
invasive cribriform carcinoma and intraductal carci-
noma could not be differentiated by the use of morpho-
logical criteria alone, additional immunohistochemical
staining for the presence of basal cells was performed.
I M M U N O H I S T O C H E M I S T R Y
Four-micrometre-thick tissue sections were cut from
selected paraffin-embedded blocks (Superfrost Micro-
scopic Slides; ThermoFisher Scientific, Bleiswijk, The
Netherlands). Slides were deparaffinised, and rehydrated
with xylene and ethanol. Endogenous peroxidase was
blocked with 0.3% H2O2 in phosphate-buffered saline,
and heat-induced antigen retrieval was accomplished
by 15 min of incubation in Tris-EDTA buffer (pH 9;
Klinipath, Duiven, The Netherlands). Mouse mono-
clonal high molecular weight cytokeratin (clone
34BE12; 1:200; Dako, Heverlee, Belgium) diluted in
normal antibody diluent (APG-500; ScyTek Laborato-
ries, West Logan, WV, USA) was incubated for 2 h at
room temperature. Antibody visualisation was per-
formed with the Envision kit (Dako) and slide counter-
staining with haematoxylin. When basal cell staining
was absent, the cribriform structure was classified as
invasive carcinoma; if sporadic, scattered or continuous
basal cells were identified, the growth pattern was clas-
sified as intraductal carcinoma.
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C L I N I C A L F O L L O W - U P
Clinical follow-up after radical prostatectomy con-
sisted of 6-monthly, and later annual, monitoring of
serum PSA levels. Biochemical recurrence was
defined as a PSA level of ≥0.2 ng/ml measured at
two separate points in time at least 3 months apart
when PSA had been undetectable after surgery, or as
a PSA increase of >2.0 ng/ml whenever serum PSA
had not declined to zero after surgery. Postoperative
lymph node and distant metastases were confirmed
by biopsy or multidisciplinary consensus. Biochemical
recurrence-free survival was defined as the time in
months from radical prostatectomy to biochemical
recurrence.
S T A T I S T I C A L A N A L Y S I S
Normally distributed, continuous variables were anal-
ysed by use of the independent sample Student’s t-
test. Pearson’s v2 test was used for categorical param-
eters. Missing PSA values (n = 27) were imputed by
use of the median PSA value. Biochemical recur-
rence-free survival was analysed with Cox propor-
tional hazards regression and visualised by the use of
Kaplan–Meier curves. Statistical analyses were per-
formed with SPSS version 24 (IBM, Chicago, IL, USA).
Results were considered to be significant when the
two-sided P-value was <0.05.
Results
P A T I E N T C H A R A C T E R I S T I C S
Of 835 radical prostatectomy specimens, 207 were
GG1 and 420 were GG2. The median age of these
627 patients at the time of surgery was 64.1 years
[interquartile range (IQR) 59.8–67.6 years], and the
median PSA level was 7.6 ng/ml (IQR 5.4–10.8 ng/
ml). Pathological tumour stage was distributed as fol-
lows: 419 (66%) pT2, 173 (28%) pT3a, and 35 (6%)
pT3b. Positive surgical margins were present in 177
(28%) cases. Pelvic lymph node dissection was per-
formed in 375 (60%) patients, of whom 12 (3%) had
lymph node metastasis.
I N V A S I V E C R I B R I F O R M A N D / O R I N T R A D U C T A L
C A R C I N O M A
Among GG2 patients, 228 (54%) had invasive cribri-
form and/or intraductal carcinoma (GG2+) and 192
(46%) did not (GG2). GG2+ patients had higher PSA
levels (12.2 ng/ml versus 9.4 ng/ml; P = 0.006), a
higher percentage of Gleason pattern 4 (24% versus
18%; P < 0.001), more frequent extraprostatic exten-
sion (pT3; 52% versus 36%; P < 0.001), more positive
surgical margins (40% versus 27%; P = 0.007) and
more lymph node metastases (8% versus 0%;
P = 0.001) than GG2– patients. GG2 patients pre-
sented with higher median PSA levels (9.4 ng/ml ver-
sus 7.0 ng/ml; P < 0.001), more frequent
extraprostatic extension (36% versus 11%; P < 0.001)
and more positive surgical margins (27% versus 17%;
P = 0.01) than GG1 patients (Table 1). None of the
GG1 or GG2 patients had metastasis at lymph node
dissection.
T E R T I A R Y G L E A S O N P A T T E R N 4 I N G G 1 P R O S T A T E
C A N C E R
GG1 prostate cancer in radical prostatectomy speci-
mens might, by definition, contain tertiary high-grade
patterns. To investigate to what extent GG2 prostate
cancer differed from GG1 prostate cancer with a ter-
tiary pattern and/or pure GG1 prostate cancer, we
analysed both GG1 subgroups separately. Tertiary
Gleason pattern 4 was present in 42 of 207 (20%) GG1
patients, of whom nine (4%) had cribriform architec-
ture. Tertiary Gleason pattern 5 was present in only
one (0.5%) patient. Patients with tertiary Gleason pat-
tern 4 had higher median PSA levels (8.4 ng/ml versus
6.6 ng/ml; P = 0.01), more frequent extraprostatic
extension (41% versus 3%; P < 0.001) and more posi-
tive surgical margins (43% versus 10%; P < 0.001)
than GG1 patients without a tertiary pattern. Although
GG2 patients had a higher percentage of Gleason pat-
tern 4 (18% versus 3%; P < 0.001) and more often
had tertiary Gleason pattern 5 (9% versus 0.5%;
P = 0.04) than GG1 patients with tertiary Gleason pat-
tern 4, PSA levels (9.4 ng/ml versus 8.4 ng/ml;
P = 0.4) and extraprostatic extension (36% versus
41%; P = 0.7) were not statistically different.
C L I N I C A L O U T C O M E
The median follow-up of the entire cohort was
59.6 months (IQR 17.5–113.9 months). Biochemical
recurrence occurred in 112 (18%) patients after a
median of 29.9 months (IQR 11.6–55.5 months).
GG2 patients had shorter biochemical recurrence-
free survival than GG1 patients, and those with crib-
riform and/or intraductal carcinoma had the worst
survival outcome (overall log rank, P < 0.001; Fig-
ure 1). The biochemical recurrence-free survival rates
of GG1 patients with tertiary Gleason pattern 4 and
GG2 patients were similar (log rank, P = 0.4).
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 76, 755–762.
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In univariate Cox regression analysis, PSA level
[hazard ratio (HR) 1.03, 95% confidence interval (CI)
1.02–1.04; P < 0.001], pT stage (HR 2.7, 95% CI
1.8–4.1; P < 0.001), percentage of Gleason pattern 4
(HR 1.03, 95% CI 1.02–1.04; P < 0.001), tertiary
Gleason pattern 5 (HR 2.4, 95% CI 1.4–4.2;
P = 0.002), positive surgical margins (HR 3.5, 95%
CI 2.4–5.1; P < 0.001), positive lymph nodes (HR
20.1, 95% CI 9.8–41.5; P < 0.001) and Grade
Groups were all significantly associated with bio-
chemical recurrence-free survival (Table 2). In multi-
variable analysis, GG2+ (HR 3.0, 95% CI 1.4–6.3;
P = 0.004), pT3 stage (HR 1.6, 95% CI 1.0–2.4;
P = 0.05), positive surgical margins (HR 2.3, 95% CI
1.6–3.5; P < 0.001) and positive lymph nodes (HR
7.2, 95% CI 3.0–17.2; P < 0.001) had independent
predictive value for biochemical recurrence-free sur-
vival. Although GG2 patients had shorter biochemi-
cal recurrence-free survival (HR 1.9, 95% CI 0.9–3.8)
than GG1 patients, this did not meet conventional
measures of significance (P = 0.08) in multivariate
analysis.
During follow-up, 13 (6%) GG2+ patients developed
distant metastases, of whom three had positive lymph
nodes at the time of radical prostatectomy. Whereas,
in total, 22 (10%) GG2+ patients had developed
either lymph node or distant metastases, no metas-
tases were identified in any GG2 patients or GG1
patients at the time of surgery or during follow-up.
Three patients died from prostate cancer, and all of
them were GG2+ patients.
Discussion
During the last decade, various studies demonstrated
that GG2 patients with invasive cribriform and/or
intraductal carcinoma have worse disease outcomes
than those without.8,9,14,16,28,29 Although it is gener-
ally accepted that GG2 patients have more aggressive
disease than GG1 patients, it is unclear whether this
is still the case when those with aggressive cribriform
pathology are excluded. In this study, we found that
46% of patients with GG2 prostate cancer at the time
Table 1. Clinicopathological characteristics of prostate cancer patients with Grade Group 1 (GG1), Grade Group 2 without
cribriform architecture (GG2) and Grade Group 2 with cribriform architecture (GG2+)
GG1 (N = 207) GG2 (N = 192) P-value* GG2+ (N = 228)
Age (years), mean (median; IQR) 62.5 (63.2; 59.8–66.7) 63.2 (64.0; 59.2–68.1) 0.26 64.2 (64.9; 60.3–67.9)
PSA (ng/ml), mean (median; IQR) 7.0 (6.3; 4.0–9.2) 9.4 (7.7; 5.4–10.5) <0.001 12.2 (8.3; 6.3–14.0)
pT stage, n (%)
T2 185 (89) 124 (64) <0.001 110 (48)
T3a 20 (10) 63 (33) 90 (40)
T3b 2 (1) 5 (3) 28 (12)
Gleason pattern 4 (%),mean (median; IQR) 0.6 (0; 0–0) 18 (15; 10–25) <0.001 24 (20; 15–30)
Invasive cribriform carcinoma, n (%) 5 (2)† 0 0.03 204 (90)
Intraductal carcinoma, n (%) 4 (2)† 0 0.05 103 (45)
Tertiary Gleason pattern 5, n (%) 1 (0.5) 18 (9) <0.001 31 (14)
Positive surgical margin status, n (%) 35 (17) 52 (27) 0.014 90 (40)
Pelvic lymph node dissection, n (%) 134 (65) 91 (47) <0.001 150 (66)
Lymph node metastasis 0 0 – 12 (8)
Biochemical recurrence, n (%) 16 (8) 29 (15) 0.02 67 (29)
Metastasis, n (%) 0 0 – 13 (6)
Disease-specific death, n (%) 0 0 – 3 (1)
IQR, interquartile range; PSA, prostate-specific antigen.
*P-values represent statistical comparison of GG1 and GG2.
†Invasive cribriform and intraductal carcinoma as tertiary components in GG1.
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of radical prostatectomy had neither invasive cribri-
form nor intraductal carcinoma. These patients had
significantly higher PSA levels, pT stage, and positive
surgical margin rates, and shorter biochemical recur-
rence-free survival, than GG1 patients. However,
none of the 399 GG1 or GG2 patients had metasta-
sis at the time of surgery or during follow-up,
whereas metastases were identified in 10% of GG2+
patients. These findings indicate that invasive cribri-
form and/or intraductal carcinoma might have the
most impact on metastatic disease progression.
Although both invasive cribriform and intraductal
carcinoma are pathological features associated with
tumour aggressiveness, it is not yet clear how to
incorporate these parameters in clinical risk stratifica-
tion. For instance, Iczkowski et al. proposed modifying
the current Grade Groups 2 to 4 by reporting the
presence of invasive cribriform and intraductal carci-
noma denoted with a ‘C’, which would increase the
number of risk groups from five to eight.30 However,
it is not yet evident whether clinically relevant differ-
ences exist between these subgroups or whether they
partially overlap. Previously, our group found that






































Figure 1. Kaplan–Meier curves for biochemical recurrence-free sur-
vival in Grade Group 1 (GG1) and Grade Group 2 prostate cancer
patients with (GG2 CR/IDC+) and without (GG2 CR/IDC) cribri-
form architecture. Log rank P < 0.001.
Table 2. Cox regression analysis of biochemical recurrence-free survival in patients with Grade Group 1 (GG1) and Grade
Group 2 prostate cancer with (GG2+) and without (GG2) cribriform architecture
Univariate analysis Multivariable analysis
HR 95% CI P-value HR 95% CI P-value
Age 0.99 0.96–1.02 0.58 0.99 0.96–1.02 0.52
PSA 1.03 1.02–1.04 <0.001 1.01 1.00–1.02 0.13
pT stage
T2 Ref. Ref.
T3a 2.7 1.8–4.1 <0.001 1.6 1.0–2.4 0.05
T3b 9.9 5.8–16.9 <0.001 2.7 1.4–5.4 0.005
Percentage Gleason 4 1.03 1.02–1.04 <0.001 1.0 1.0–1.02 0.69
Tertiary Gleason pattern 5 2.4 1.4–4.2 0.002 1.4 0.7–2.6 0.34
Positive surgical margin status 3.5 2.4–5.1 <0.001 2.3 1.6–3.5 <0.001
Lymph node metastasis 20.1 9.8–41.5 <0.001 7.2 3.0–17.2 <0.001
Grade Group
GG1 Ref. Ref.
GG2 2.7 1.4–4.9 0.002 1.9 0.9–3.8 0.08
GG2+ 6.2 3.6–10.7 <0.001 3.0 1.4–6.3 0.004
CI, confidence interval; HR, hazard ratio; PSA, prostate-specific antigen.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 76, 755–762.
Cribriform-negative Grade Group 2 prostate cancer 759
recurrence rates and disease-specific survival to those
of GG1 patients.15–17 In the current study, we demon-
strate that GG2 prostate cancer is associated with sig-
nificantly worse clinicopathological characteristics and
outcome than GG1 prostate cancer. These findings on
radical prostatectomy specimens differ slightly from
those of our previous study on biopsy specimens.17
This might be explained by biopsy sampling artefacts,
as upgrading occurs in up to 40% of biopsy GG1 and
GG2 patients.1,31 Furthermore, recent studies have
indicated that biopsies have a moderate sensitivity of
43–47% for detecting cribriform architecture.21,22
Despite moderate concordance of growth patterns
between biopsy and radical prostatectomy specimens,
incorporation of cribriform architecture into the Grade
Groups has better discriminative value for disease-
specific survival and metastasis-free survival.20 In biop-
sies, we previously demonstrated that subtraction of
one point of the Grade Group if no cribriform architec-
ture was present was a simple and valuable modifica-
tion of the current prostate cancer grading scheme.20
Metastasis-free survival rates of GG2 and GG1
patients were similar in both biopsy and radical
prostatectomy studies.17 GG1 prostate cancer at the
time of radical prostatectomy is known to have a very
low if any risk of metastasis and disease-specific
death.5,32–39 As no metastases were identified in pelvic
lymph node dissection or during follow-up of GG2
patients, this population also seems to have a low risk
of metastatic progression. This indicates that invasive
cribriform and intraductal carcinoma, in particular,
might have an impact on the biological potential for
metastatic disease to develop. In contrast, postopera-
tive biochemical recurrence-free survival is also related
to tumour volume parameters and surgical technique,
which do not necessarily reflect biological derange-
ment caused by the disease. Cribriform architecture
has been associated with genomic instability and has
been clonally related to lymph node metastasis, which
might provide a rationale for its aggressive biological
behaviour.40–43
Forty-two of 207 (20%) GG1 patients had tertiary
Gleason pattern 4. These patients had worse clinico-
pathological features than pure GG1 patients, and
were more similar to GG2 patients. This finding is
in line with those of others reporting on the clinical
relevance of tertiary patterns, and underlines the
importance of reporting them.44–53
The strong point of this study is the detailed histo-
logical evaluation of the radical prostatectomy speci-
mens, including recently identified clinically relevant
pathological parameters. Limitations of this retrospec-
tive investigation are its relatively low number of
patients and its limited median follow-up time of
59.6 months. The identification of small differences
in metastasis-free survival would require a large
number of low-risk patients with long-term follow-up.
Finally, although we made significant efforts to differ-
entiate intraductal and invasive cribriform carcinoma,
this distinction might be impossible in some cases,
even with the use of immunohistochemistry.
In conclusion, patients with GG2 prostate cancer
at the time of radical prostatectomy have more
advanced disease and shorter biochemical recurrence-
free survival than GG1 patients. However, both
groups have a very low risk of developing metastatic
disease.
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